PMID- 21241740
OWN - NLM
STAT- MEDLINE
DCOM- 20110607
LR  - 20111117
IS  - 1872-9096 (Electronic)
IS  - 0166-3542 (Linking)
VI  - 89
IP  - 3
DP  - 2011 Mar
TI  - Human leukocyte antigen class I and class II genes polymorphisms might be 
      associated with interferon alpha therapy efficiency of chronic hepatitis B.
PG  - 189-92
LID - 10.1016/j.antiviral.2011.01.001 [doi]
AB  - Certain host genetic polymorphisms in human leukocyte antigen (HLA) genes are 
      reported to be associated with response to interferon alpha (IFNalpha) therapy. Two 
      hundred and eighteen IFNalpha treatment-naive chronic hepatitis B (CHB) patients were 
      enrolled in the present study. HLA-A, B, C and DQA1, DQB1, DRB1 gene alleles were 
      detected by polymerase chain reaction-sequencing based typing (PCR-SBT) and 
      PCR-sequence specific primer (PCR-SSP), respectively. Frequencies of 
      HLA-DQB1*0303 and DRB1*08 in response group were clearly lower than those in 
      nonresponse group (P=0.019, OR=1.81, 95%CI=1.07-3.15; P=0.031, OR=2.43, 
      95%CI=1.02-5.98, respectively). Frequencies of haplotype *1101-*4601-*0102 
      (HLA-A, B, C) and haplotype *0302-*0303-*09 (HLA-DQA1, DQB1, DRB1) were clearly 
      lower than those in nonresponse group (P=0.009, OR=4.84, 95%CI=1.29-19.48; 
      P=0.031, OR=1.94, 95%CI=1.01-3.73, respectively). These results suggest that 
      patients with HLA-DQB1*0303 or DRB1*08 alleles, and haplotype *1101-*4601-*0102 
      (HLA-A, B, C) or haplotype *0302-*0303-*09 (HLA-DQA1, DQB1, DRB1), might be less 
      responsive to IFNalpha treatment.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Zhu, Xilin
AU  - Zhu X
AD  - National Laboratory of Medical Molecular Biology, Institute of Basic Medical 
      Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking 
      Union Medical College, Beijing, PR China.
FAU - Du, Te
AU  - Du T
FAU - Wu, Xiaopan
AU  - Wu X
FAU - Guo, Xinhui
AU  - Guo X
FAU - Niu, Nifang
AU  - Niu N
FAU - Pan, Liping
AU  - Pan L
FAU - Xin, Zhenhui
AU  - Xin Z
FAU - Wang, Li
AU  - Wang L
FAU - Li, Zhuo
AU  - Li Z
FAU - Li, Hui
AU  - Li H
FAU - Liu, Ying
AU  - Liu Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110115
PL  - Netherlands
TA  - Antiviral Res
JT  - Antiviral research
JID - 8109699
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interferon-alpha)
SB  - IM
MH  - Female
MH  - Gene Frequency
MH  - Haplotypes
MH  - Hepatitis B, Chronic/*drug therapy
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Histocompatibility Antigens Class II/*genetics
MH  - Humans
MH  - Immunologic Factors/*administration & dosage
MH  - Interferon-alpha/*administration & dosage
MH  - Male
MH  - Polymerase Chain Reaction
MH  - *Polymorphism, Genetic
MH  - Sequence Analysis, DNA
MH  - Treatment Outcome
EDAT- 2011/01/19 06:00
MHDA- 2011/06/08 06:00
CRDT- 2011/01/19 06:00
PHST- 2010/08/17 00:00 [received]
PHST- 2010/12/01 00:00 [revised]
PHST- 2011/01/10 00:00 [accepted]
PHST- 2011/01/19 06:00 [entrez]
PHST- 2011/01/19 06:00 [pubmed]
PHST- 2011/06/08 06:00 [medline]
AID - S0166-3542(11)00003-9 [pii]
AID - 10.1016/j.antiviral.2011.01.001 [doi]
PST - ppublish
SO  - Antiviral Res. 2011 Mar;89(3):189-92. doi: 10.1016/j.antiviral.2011.01.001. Epub 
      2011 Jan 15.